Laekna (HKG:2105) commenced its investigational new drug-enabling study for its LAE123 drug, according to a Thursday filing with the Hong Kong Exchange.
LAE123 inhibits activin type II receptors or ActRIIA/IIB and helps prevent sarcopenia or muscle weakness.
The company has advanced the drug to pre-clinical candidate declaration, the filing said.
Price (HKD): $15.04, Change: $-0.22, Percent Change: -1.44%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。